Addex Therapeutics Ltd. filings document a foreign private issuer and ADR-linked clinical-stage biotechnology company focused on small-molecule allosteric modulators. Form 6-K reports furnish press releases, financial results, interim condensed consolidated financial statements, MD&A, iXBRL exhibits, and risk-factor updates incorporated into Form F-3 and Form S-8 registration statements.
The disclosures cover pipeline programs such as GABAB PAM candidates, mGlu receptor modulators, ADX71149, and Neurosterix-related NTX-253, along with collaboration and licensing arrangements, strategic investments, cash resources, governance, equity-plan registrations, and foreign-issuer reporting under Form 20-F.
Addex Therapeutics Ltd. (ADXN) reported that chief executive officer and director Timothy Mark Dyer had his equity awards economically repriced on September 2, 2026, without any net change in the number of shares he holds. The Form 4 shows paired dispositions to and acquisitions from the issuer that reflect this repricing mechanics.
The filing covers 16,413,787 shares of common stock acquired previously through a deferred strike price payment plan and 3,369,796 stock options. For the deferred strike plan units, initial strike prices of $0.16 and $0.053 per share were reduced to $0.032 per share following a Remuneration Committee decision, with all other terms unchanged. Separately, the exercise price of the covered options was reduced from $0.062 to $0.032 per share, with no cash changing hands in these reporting entries.
The company states that these transactions are exempt under Rule 16b-6(d) and Rule 16b-3 under the Exchange Act. Exercise and strike prices are reported in U.S. dollars based on an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026.
Addex Therapeutics Ltd. (ADXN) discloses in Amendment No. 10 to a Schedule 13D that its Chief Executive Officer and director, Timothy Mark Dyer, beneficially owns 19,165,714 ordinary shares, representing approximately 9.01% of the company’s ordinary shares based on 210,292,217 shares outstanding as of August 26, 2026. This holding consists of 16,848,979 outstanding ordinary shares and 2,316,735 shares issuable upon exercise of options that are exercisable within 60 days of September 2, 2026, over which he has sole voting and dispositive power.
The amendment is being filed following a reduction of the strike price of all relevant option units to CHF0.026 per share, and a separate option grant for 3,369,796 shares repriced to CHF0.0268 on September 2, 2026, under deferred strike price payment plans. Dyer states he has no present plans for major corporate actions such as mergers, asset sales, changes in board composition, or capital structure, but he may reconsider his position and transactions in the shares based on his ongoing assessment of the issuer and market conditions.
Addex Therapeutics Ltd. (ADXN) received an amended Schedule 13D (Amendment No. 9) from its Chief Executive Officer and director, Timothy Mark Dyer, updating his ownership position following dilution from additional share issuances. As of August 26, 2026, Dyer beneficially owns 19,095,510 ordinary shares of Addex, including shares underlying options exercisable within 60 days.
This stake represents approximately 8.89% of Addex’s ordinary shares, based on 210,292,217 ordinary shares outstanding as reported on August 26, 2026. His holdings consist of 16,848,979 issued shares and 2,246,531 shares issuable upon option exercise. The securities were acquired over many years through founder shares, private placements, option exercises, and share and option compensation for his service as CEO. Dyer reports sole voting and dispositive power over all of these shares and states he has no present specific plans for corporate actions, while reserving the right to change his intentions.
Addex Therapeutics Ltd. (ADXN) reported raising gross proceeds of USD 2.8 million (CHF 2.2 million) through the sale of 437,869 American Depositary Shares (ADSs), representing 52,544,280 shares, under its At the Market (ATM) offering agreement with H.C. Wainwright & Co. Management states that, following this sale, the company’s cash runway is extended to the fourth quarter of 2027. The number of outstanding shares, excluding treasury shares, increased to 210,292,217 shares, while issued shares remained at 218,654,496 shares. The accompanying press release is incorporated by reference into Addex’s existing Form F-3 and Form S-8 registration statements.
Addex Therapeutics filed a Form 6-K to furnish a press release describing new preclinical research on ADX71743, a selective negative allosteric modulator of metabotropic glutamate receptor 7 (mGlu7). In animal models, ADX71743 increased wakefulness, reduced REM and non-REM sleep, and altered stress-related neurotransmitters.
The findings, published in the International Journal of Neuropsychopharmacology, add to evidence that mGlu7 is a promising target for central nervous system disorders linked to dysregulated stress responses. The report also reiterates key risk disclosures and incorporates the press release by reference into Addex’s existing Form F-3 and Form S-8 registration statements.
Addex Therapeutics Ltd reported that shareholders approved all Board of Directors’ proposals at the 2026 Annual General Meeting. The votes represented 29.35% of the company’s outstanding capital, confirming support for the 2025 annual report, consolidated and statutory financial statements, and the compensation report.
Shareholders approved compensation for the board and executive management and granted discharge to both for their 2025 activities. All current board members, including Chairman Dr. Vincent Lawton, were re-elected, as were BDO SA as auditor for the 2026 business year and Robert P. Briner as independent voting rights representative until the 2027 AGM.
Investors also backed amendments to the Articles of Association related to an increase of the capital band and conditional share capital, preserving flexibility for future equity-related actions. The filing reiterates the company’s focus on allosteric modulators for neurological disorders and notes its 20% equity interest in Neurosterix US Holdings LLC.
Addex Therapeutics Ltd reports unaudited Q1 2026 results showing a small, lean operation but serious funding pressure. The company generated no revenue and recorded a net loss of CHF 1.71 million, largely driven by operating loss of CHF 0.48 million and a CHF 1.23 million share of losses from its 20% stake in Neurosterix.
Cash and cash equivalents fell to CHF 0.94 million as of March 31, 2026 after negative operating cash flow of CHF 0.77 million, only partly offset by CHF 0.07 million of cash from selling treasury shares. The company explicitly states its cash is expected to fund operations only through the end of July 2026, and concludes that there is a material uncertainty raising substantial doubt about its ability to continue as a going concern without new capital or monetization of assets.
Addex Therapeutics Ltd filed a Form 6-K announcing that its 2026 Annual General Meeting will be held on June 29, 2026 at 11:00 am CEST at Campus Biotech in Geneva. Shareholders will be asked to approve the 2025 annual and consolidated financial statements, vote consultatively on the 2025 compensation report, decide on appropriation of results and grant discharge to the board and executive management.
The agenda also includes re-elections of all current board members and the chairman, re-elections to the Compensation Committee, re-appointment of the auditor, and re-election of the independent voting rights representative. Shareholders will consider amendments to the Articles of Association to increase the capital band and conditional share capital, and will vote on future compensation for the board and executive management. The filing reiterates that investors should review existing SEC risk factors and notes that the press release is incorporated by reference into existing F-3 and S-8 registration statements.
Addex Therapeutics Ltd files its annual report on Form 20-F, highlighting a development-stage biotech business with ongoing losses and tight liquidity. The company incurred an accumulated loss of CHF 360 million since inception and reported a net loss of CHF 6.7 million for the year ended December 31, 2025, compared to a net profit of CHF 7.1 million a year earlier, when results benefited from a business sale.
As of December 31, 2025, Addex held cash and cash equivalents of CHF 1.6 million and expects this to fund operations only through mid‑June 2026, so it will need significant additional capital from partnerships, IP monetization and equity offerings. The company sold its allosteric modulator discovery platform and certain preclinical programs to Neurosterix in April 2024 for CHF 5.0 million and a 20% equity stake, and now relies heavily on partners such as Indivior and Neurosterix for development, infrastructure and potential milestone revenue. The filing details extensive risks around financing, regulatory approvals, reliance on third parties, intellectual property, data protection, healthcare policy changes and potential Nasdaq delisting pressure.
Addex Therapeutics reported full-year 2025 results with a net loss of CHF 6.7 million, compared with a profit of CHF 7.1 million in 2024, and cash and cash equivalents of CHF 1.6 million at December 31, 2025. Income from continuing operations fell to CHF 0.2 million as the research phase of the Indivior collaboration ended mid-2024. R&D expenses declined to CHF 0.7 million, while G&A remained stable at CHF 2.3 million. Losses from associates increased to CHF 4.0 million due to its 20% stake in Neurosterix US Holdings LLC. Shareholders’ equity decreased to CHF 4.8 million.
Operationally, Addex advanced its GABAB PAM program for chronic cough, progressed dipraglurant (an mGlu5 NAM) toward clinical studies in brain injury recovery, and regained rights to the Phase 2 mGlu2 PAM asset ADX71149. It also entered an option and collaboration agreement with Sinntaxis on mGlu5 NAM for brain injury and maintained a strategic investment portfolio, including Neurosterix and Stalicla. The company scheduled a conference call on April 30, 2026, to discuss these results and its pipeline progress.